Publications by authors named "Benjamin Hebraud"

Claim this Profile
R
Real-World Evidence Supports Venetoclax as an Additional Option for Patients With t(11;14) Myeloma.
Jules Higué, Gaetan Basile, Titouan Cazaubiel, Julie Gay, Guillaume Béziat

Clin Lymphoma Myeloma Leuk· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.
Jill Corre, Laure Vincent, Philippe Moreau, Benjamin Hebraud, Cyrille Hulin

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial.
Aurore Perrot, Cyrille Touzeau, Jerome Lambert, Cyrille Hulin, Denis Caillot, Benjamin Hebraud

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.
Laura Rosiñol, Benjamin Hebraud, Albert Oriol, Anne-Laurène Colin, Rafael Ríos Tamayo

Front Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03).
Zoe van de Wyngaert, Florent Malard, Cyrille Hulin, Denis Caillot, Clara Mariette, Benjamin Hebraud

Clin Hematol Int· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Benjamin Hebraud

Blood· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.
Thierry Facon, Gordon Cook, Saad Z Usmani, Cyrille Hulin, Shaji Kumar, Benjamin Hebraud

Leukemia· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier

Blood· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.
Philippe Moreau, Benjamin Hebraud, Thierry Facon, Xavier Leleu, Cyrille Hulin

Immunotherapy· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Murielle Roussel, Philippe Moreau, Benjamin Hebraud, Kamel Laribi, Arnaud Jaccard

Lancet Haematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk.
Jill Corre, Lydia Montes, Elodie Martin, Aurore Perrot, Denis Caillot

Haematologica· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Murielle Roussel, Benjamin Hebraud, Cyrille Hulin, Aurore Perrot, Denis Caillot

Leuk Lymphoma· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells.
Nicolas Espagnolle, Benjamin Hebraud, Jean-Gérard Descamps, Mélanie Gadelorge, Marie-Véronique Joubert

Stem Cells Int· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells.
Cédric Ménard, Joëlle Dulong, David Roulois, Benjamin Hébraud, Léa Verdière

Stem Cells· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An ulceration on the tongue: A case report.
Emmanuelle Vigarios, Aurore Siegfried, Benjamin Hebraud, Vincent Sibaud, Delphine Maret

Oral Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow.
Céline Mazzotti, Laure Buisson, Sabrina Maheo, Aurore Perrot, Marie-Lorraine Chretien

Blood Adv· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DKK1 and sclerostin are early markers of relapse in multiple myeloma.
Charlotte Mabille, Adeline Ruyssen-Witrand, Yannick Degboe, Isabelle Gennero, Herve Avet Loiseau, Benjamin Hebraud

Bone· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.
Guillemette Fouquet, Kym Ie Snell, Stéphanie Guidez, Susanna Schraen, Eileen Boyle, Benjamin Hebraud

Leuk Lymphoma· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma.
Felicity Kendrick, Neil D Evans, Bertrand Arnulf, Hervé Avet-Loiseau, Olivier Decaux, Benjamin Hebraud

Front Physiol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
Marie-Lorraine Chretien, Jill Corre, Valerie Lauwers-Cances, Florence Magrangeas, Alice Cleynen, Benjamin Hebraud

Blood· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
Benjamin Hebraud, Florence Magrangeas, Alice Cleynen, Valerie Lauwers-Cances, Marie-Lorraine Chretien

Blood· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients.
Lucie Oberic, Willy Vaillant, Benjamin Hebraud, Christian Recher, Etienne Suc

Eur J Haematol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
Murielle Roussel, Valérie Lauwers-Cances, Nelly Robillard, Cyrille Hulin, Xavier Leleu, Benjamin Hebraud

J Clin Oncol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.
Marie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, Cyrille Hulin, Gerald Marit

Haematologica· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation.
Guillemette Fouquet, Benjamin Hebraud, Sylvain Garciaz, Anne Marie Stoppa, Murielle Roussel

J Cancer· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis